05 September 2018Immunocore strengthens IP position in the field of TCR-based therapeutics
20 August 2018Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
16 July 2018Immunocore Announces Management Change
04 June 2018Immunocore Presents New IMCgp100-102 Data that Show Durable Response and Robust Overall Survival Rate in Patients with Metastatic Uveal Melanoma
22 May 2018Immunocore to Present New Data from IMCgp100-102 Trial in Metastatic Uveal Melanoma at 2018 ASCO Annual Meeting
21 May 2018Immunocore wins Large Business of the Year at the 2018 Vale4Business Awards
05 April 2018Immunocore Publishes Gender Pay Report
08 February 2018Immunocore Announces Leadership Change
04 January 2018Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-Executive Directors
11 December 2017Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma
Sign-up to receive news email alerts
By continuing to use this website you will be agreeing to our privacy policy and the use of cookies.
